<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Psychiatry</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/382F3EEB-8130-4EB4-9046-EC4190AD6E07"><gtr:id>382F3EEB-8130-4EB4-9046-EC4190AD6E07</gtr:id><gtr:firstName>Philip</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Cowen</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G9102334"><gtr:id>72963262-0AC5-416F-B7FC-4C9A5F531EA7</gtr:id><gtr:title>Clinical Psychopharmacology of 5-HT</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G9102334</gtr:grantReference><gtr:abstractText>Clinical depression is a common illness, often beginning during the teenage years, which can recur throughout a lifetime. The recurrent nature of clinical depression, together with the burden it places on sufferers and their families, makes this condition second only to heart disease in terms of suffering and disability. Understanding the biochemical changes in the brain in depression will help us to devise better treatments and also improve efforts at prevention. New advances in brain imaging now allow us to study the biochemistry of the brain directly in patients and healthy volunteers. Using a special radio-labelled marker with an imaging examination called positron emission tomography (PET) we have found a decrease in certain kinds of brain receptors for a chemical messenger called serotonin (also called 5-HT) in depressed patients, both when they are ill and after recovery. This suggests that abnormal function of 5-HT may play a role in making people vulnerable to developing depression. In the present research programme will use PET imaging to study other kinds of 5-HT receptors to better understand the range of brain 5-HT receptor abnormalities in depression. In addition we will use another kind of brain imaging called magnetic resonance spectroscopy (MRS) to see how 5-HT interacts with special neurons in the cerebral cortex that use a chemical messenger called GABA. We believe that the interactions between 5-HT and GABA may be very important in helping us understand the cause of depression and in developing more effective methods of treatment. Finally we will study young people who we know are at risk of depression to see if altered 5-HT activity predates the onset of depression and might therefore be useful as a means of predicting which people are most at risk. If changes in 5-HT do predate the onset of depression it is possible that a relatively simple means of modifying 5-HT (for example, a dietary intervention) could be used to prevent the onset of depression in young people at risk.</gtr:abstractText><gtr:technicalSummary>Recurrent major depression is a common, often life-long condition, with a high morbidity. The neurobiology of the disorder is not well understood but abnormalities in brain 5-HT function appear to play an important role in the pathophysiology of both depression and the therapeutic effects of antidepressant treatment. The present proposal aims to build on our findings with both ligand PET imaging and 5-HT pharmacological challenge studies that depressed patients have abnormalities in aspects of brain 5-HT function that persist into clinical recovery. We will continue to use PET imaging to identify additional abnormalities in brain 5-HT receptors in depressed patients and examine their status as trait or state markers. Basic studies suggest that cortical GABA-ergic interneurones are a key target for ascending 5-HT pathways and that changes in GABA activity in mood-related circuitry could mediate the therapeutic effects of 5-HT promoting agents. We will therefore use proton magnetic resonance spectroscopy (MRS) to examine GABA-5-HT interactions in both healthy subjects and those at risk of depression. In addition we will use a 5-HT neuroendocrine challenge test and a 5-HT-sensitive emotional processing task to identify neurobiological abnormalities in young people at high risk of depression. Our long-term aim is to devise feasible preventative strategies to decrease the risk of early-onset, recurrent depression in this vulnerable group.</gtr:technicalSummary><gtr:fund><gtr:end>2008-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1993-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>3397484</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Medicine</gtr:department><gtr:description>Oxford Biomedical Research Centre</gtr:description><gtr:id>6885EEBE-D0C0-4E81-9CFF-180E498B613B</gtr:id><gtr:impact>papers submitted fro publication</gtr:impact><gtr:outcomeId>HbYPDHG5cXE-1</gtr:outcomeId><gtr:partnerContribution>provision of patients and immunological expertise</gtr:partnerContribution><gtr:piContribution>Study of the effect of interferon alpha on brain neurochemistry using MRS</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Pharmacology</gtr:department><gtr:description>Pharmacology</gtr:description><gtr:id>F33E137D-E8F6-4D2A-8B2B-A418DA1B955B</gtr:id><gtr:impact>Grant from BBSRC</gtr:impact><gtr:outcomeId>ANL4rSnEEmU-1</gtr:outcomeId><gtr:partnerContribution>basic animal studies which act as platform for human work.</gtr:partnerContribution><gtr:piContribution>Collaboration on clinical translation of a lithium-mimetic</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Cheltenham Science Festival</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>575101C1-5540-415A-9DA8-B97215EC3915</gtr:id><gtr:impact>200 people attended talk on antidepressants by Catherine Harmer. Led to intense audience discussion and newspaper articles.

Newspaper articles and journalists contacting the lab</gtr:impact><gtr:outcomeId>aP4vexxYEgV</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press Conference Royal Society</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3B46A3CD-1FB5-47A3-B805-3291246EF0DC</gtr:id><gtr:impact>Press Conference arranged by Royal Society to talk about burden of mental health problems

articles in media</gtr:impact><gtr:outcomeId>BC81FBB8EC0</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit Oxford</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>525F4D57-4756-47A9-81FB-82A74382179A</gtr:id><gtr:impact>Attending schools to talk about biological research in mental health

Requests for work placements</gtr:impact><gtr:outcomeId>C3C54CAB5F9</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>430000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Research Grant</gtr:description><gtr:end>2012-11-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>43187231-8445-4040-AF5A-9401AF72D0E6</gtr:id><gtr:outcomeId>04F6EFDFA370</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Research Grant</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>63E2F123-FD80-4073-BDE5-05D2864A3F6A</gtr:id><gtr:outcomeId>EDE133F57AC0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NICE Panel on GAD</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D2633E35-2A4E-46F2-9704-F83FB6D43C12</gtr:id><gtr:impact>An evidence-based guideline on the treatment of generalised anxiety disorder. Improvements in clinical practice and management.</gtr:impact><gtr:outcomeId>Wx3mMsTKQV1</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>BAP guideline on depression</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>84393453-F716-4B98-8C31-4A595EEB675E</gtr:id><gtr:impact>Improvement in the pharmacological management of depression</gtr:impact><gtr:outcomeId>Pq3vEe56M8g</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>P1Vital</gtr:companyName><gtr:description>Interface between Oxford University Dept of Psychiatry and Pharmaceutical Industry. Applying novel methods of drug discovery to screen for new antidperessants at phase 1-2; http://www.p1vital.com/</gtr:description><gtr:id>A9B92DA8-1EEB-4A52-A2BD-9E0066D5EB20</gtr:id><gtr:impact>Income generation from Industry through take up of screening studies</gtr:impact><gtr:outcomeId>B76828EA966</gtr:outcomeId><gtr:url>http://www.p1vital.com</gtr:url><gtr:yearCompanyFormed>2006</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>9AC2A145-F890-482C-A4F6-AE6F711C042A</gtr:id><gtr:title>Affective modulation of anterior cingulate cortex in young people at increased familial risk of depression.</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/883e93881f45f4205fb363e9972ff32e"><gtr:id>883e93881f45f4205fb363e9972ff32e</gtr:id><gtr:otherNames>Mannie ZN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn><gtr:outcomeId>1B97015A523</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2069534E-1CA6-4820-AB82-A56301CE6459</gtr:id><gtr:title>Antidepressant drug treatment modifies the neural processing of nonconscious threat cues.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9714622cbdf3aade07f0e4b795152598"><gtr:id>9714622cbdf3aade07f0e4b795152598</gtr:id><gtr:otherNames>Harmer CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>004D2146C21</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>642C0C74-F200-4254-AE3D-8819168D62A8</gtr:id><gtr:title>Impaired emotional categorisation in young people at increased familial risk of depression.</gtr:title><gtr:parentPublicationTitle>Neuropsychologia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/883e93881f45f4205fb363e9972ff32e"><gtr:id>883e93881f45f4205fb363e9972ff32e</gtr:id><gtr:otherNames>Mannie ZN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0028-3932</gtr:issn><gtr:outcomeId>824AD83F836</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB87A7C5-4C3A-4CE4-BBD5-1C53899F694C</gtr:id><gtr:title>Emotional bias and waking salivary cortisol in relatives of patients with major depression.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0e173c523a6f053c2e2358bc12d898a"><gtr:id>c0e173c523a6f053c2e2358bc12d898a</gtr:id><gtr:otherNames>Le Masurier M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>9C27B9E3B9A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>778FABAD-2B27-44B2-A7F5-62C52DFB51B1</gtr:id><gtr:title>Single dose antidepressant administration modulates the neural processing of self-referent personality trait words.</gtr:title><gtr:parentPublicationTitle>NeuroImage</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/33b6ce983acf43deeebe8ea421654844"><gtr:id>33b6ce983acf43deeebe8ea421654844</gtr:id><gtr:otherNames>Miskowiak K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1053-8119</gtr:issn><gtr:outcomeId>D00BD581817</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B38EFF18-3766-4F69-91B2-57C161EA5277</gtr:id><gtr:title>Dissociable effects of acute antidepressant drug administration on subjective and emotional processing measures in healthy volunteers.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9714622cbdf3aade07f0e4b795152598"><gtr:id>9714622cbdf3aade07f0e4b795152598</gtr:id><gtr:otherNames>Harmer CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>0CFE43630DB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2ACD4DAA-ECA7-45E1-A3E0-B27AAB25CF88</gtr:id><gtr:title>Tryptophan depletion does not lower brain GABA levels in healthy volunteers.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f36a0b46d325daf7d58d5c21cdcf6fda"><gtr:id>f36a0b46d325daf7d58d5c21cdcf6fda</gtr:id><gtr:otherNames>Selvaraj S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>71CEC094349</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4852DF9-79A3-4E33-BE40-E3478023382A</gtr:id><gtr:title>Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [(11)C]MDL 100,907.</gtr:title><gtr:parentPublicationTitle>The American journal of psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/606788fd0f3df58c3e78973256862006"><gtr:id>606788fd0f3df58c3e78973256862006</gtr:id><gtr:otherNames>Bhagwagar Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0002-953X</gtr:issn><gtr:outcomeId>81A40AAE354</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47CA8256-69C0-4641-A5E7-2F2678228FCF</gtr:id><gtr:title>Short-term antidepressant treatment and facial processing. Functional magnetic resonance imaging study.</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66e098825713ff2a824ed36b33d241e9"><gtr:id>66e098825713ff2a824ed36b33d241e9</gtr:id><gtr:otherNames>Norbury R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn><gtr:outcomeId>3B578A71FD9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2074F364-C9EE-4A5C-9A97-20C6BC69F291</gtr:id><gtr:title>Reduction in occipital cortex gamma-aminobutyric acid concentrations in medication-free recovered unipolar depressed and bipolar subjects.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/606788fd0f3df58c3e78973256862006"><gtr:id>606788fd0f3df58c3e78973256862006</gtr:id><gtr:otherNames>Bhagwagar Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>A046BF516F9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E07A215-2141-465F-A778-3DC878B6EAB8</gtr:id><gtr:title>Tryptophan supplementation induces a positive bias in the processing of emotional material in healthy female volunteers.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c2a8c889869049188f716ea80809693"><gtr:id>4c2a8c889869049188f716ea80809693</gtr:id><gtr:otherNames>Murphy SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>346954AA38A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D68862FD-6127-4EE7-BA62-320F04246D12</gtr:id><gtr:title>5-HTT binding in recovered depressed patients and healthy volunteers: a positron emission tomography study with [11C]DASB.</gtr:title><gtr:parentPublicationTitle>The American journal of psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/606788fd0f3df58c3e78973256862006"><gtr:id>606788fd0f3df58c3e78973256862006</gtr:id><gtr:otherNames>Bhagwagar Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0002-953X</gtr:issn><gtr:outcomeId>18CA4597AC5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8AB02287-859D-4606-BF59-4F3C7906D998</gtr:id><gtr:title>Differential effects of citalopram and reboxetine on cortical Glx measured with proton MR spectroscopy.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d843fcca896da302a2ab0b978fbfbba9"><gtr:id>d843fcca896da302a2ab0b978fbfbba9</gtr:id><gtr:otherNames>Taylor M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>E511C1188B3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C80F6ED-57DF-41FB-B01F-6CF48F193496</gtr:id><gtr:title>Human 5-HT transporter availability predicts amygdala reactivity in vivo.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6473e6039d1a8b24ee91f11bc511c084"><gtr:id>6473e6039d1a8b24ee91f11bc511c084</gtr:id><gtr:otherNames>Rhodes RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>8DC45CBF97D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF14F74C-0F42-4AA5-966A-45AE1EA32D84</gtr:id><gtr:title>Effects of citalopram infusion on the serotonin transporter binding of [11C]DASB in healthy controls.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f14f4bf864a08d8c9ae797010a34bb31"><gtr:id>f14f4bf864a08d8c9ae797010a34bb31</gtr:id><gtr:otherNames>Hinz R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>57853044177</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F2D3CAA4-C32A-477B-B378-505BF3AA89AB</gtr:id><gtr:title>Normal glutamate but elevated myo-inositol in anterior cingulate cortex in recovered depressed patients.</gtr:title><gtr:parentPublicationTitle>Journal of affective disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/880cf52474bd701e7fe0e2f26464865f"><gtr:id>880cf52474bd701e7fe0e2f26464865f</gtr:id><gtr:otherNames>Taylor MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0165-0327</gtr:issn><gtr:outcomeId>D9E2991A5DF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1555C7DB-6EA4-4150-9B3C-87F661A280B0</gtr:id><gtr:title>Effects of alpha-lactalbumin on emotional processing in healthy women.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ad6f6ea635bc308f88f6d140568c119"><gtr:id>1ad6f6ea635bc308f88f6d140568c119</gtr:id><gtr:otherNames>Scrutton H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>1960092A619</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FAD9FC1B-2EAE-4744-8E5B-A7A42106F4EF</gtr:id><gtr:title>The effects of reboxetine on emotional processing in healthy volunteers: an fMRI study.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66e098825713ff2a824ed36b33d241e9"><gtr:id>66e098825713ff2a824ed36b33d241e9</gtr:id><gtr:otherNames>Norbury R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>8A1CBE7A42D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DFDB4F34-94FC-446C-A358-EE7E661AC4AE</gtr:id><gtr:title>A single dose of citalopram increases fear recognition in healthy subjects.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/703566a36c909175a74bbc59ec5b81a9"><gtr:id>703566a36c909175a74bbc59ec5b81a9</gtr:id><gtr:otherNames>Browning M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>B17C63B0D55</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E34E280-0DF4-4634-8EFB-2EC9D6837F55</gtr:id><gtr:title>Oxytocin enhances processing of positive versus negative emotional information in healthy male volunteers.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e9182640a623f56707624b00a3d534b"><gtr:id>3e9182640a623f56707624b00a3d534b</gtr:id><gtr:otherNames>Di Simplicio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>06686C01C79</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F5A960F-7BD1-475B-889B-00556BC0D237</gtr:id><gtr:title>Increased waking salivary cortisol levels in young people at familial risk of depression.</gtr:title><gtr:parentPublicationTitle>The American journal of psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/883e93881f45f4205fb363e9972ff32e"><gtr:id>883e93881f45f4205fb363e9972ff32e</gtr:id><gtr:otherNames>Mannie ZN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0002-953X</gtr:issn><gtr:outcomeId>0CFF60C1631</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G9102334</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>3C193D18-12BD-4B15-8347-037BA623E0FF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Mental Health</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>